Acetyl hexapeptide-8: what has been measured about safety

Acetyl hexapeptide-8 has a documented safety record, which is unusual in this catalogue and is a consequence of it being a lawfully sold cosmetic ingredient rather than a research chemical. The Expert Panel for Cosmetic Ingredient Safety published an assessment in 2025 reaching a conclusion of safety in cosmetics in the present practices of use, bounded at concentrations up to 0.005 per cent, and stating that the available data are insufficient to reach that conclusion at concentrations greater than 0.005 per cent [7].

Both halves of that belong on this page. The second half is a statement about what has been submitted, not a finding that anything is harmful, and a reader who takes it as a warning has read it wrong. A page that omits it has left out the operative limit.

Beyond the panel there are three further primary records: two randomised trials run by a national institute, both of which posted their adverse event tables to the registry and both of which are reproduced in full below [17] [18], one independent laboratory's measurement of what the peptide does to dividing cells [13], and a single published case report about an injection procedure that is not how this ingredient is labelled or sold [14]. This page reports all four, and closes with the measurement that bounds them.

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Every sentence below reports what a named source measured, concluded or searched, in what system, and what it found. Where the answer is that nobody has looked, the page says which study would have looked.

This page publishes no dose, no schedule, no route instruction and no list of people who should avoid anything. A list of who should not use a compound is a directions-for-use document, and it only makes sense if the reader is going to use the thing. What replaces it is a description of the compound and its record, written about the molecule rather than about the reader.

One distinction runs through everything here. This is a cosmetic ingredient formulated to be applied to the surface of skin, and almost every record below concerns that route. One does not: a published case report describes injections, which bypass the barrier entirely. Where a record concerns an exposure other than the labelled one, the page says so in the same sentence, because those are different exposures rather than stronger versions of the same one.

What has been measured

The industry panel's conclusion, in both halves

The Expert Panel for Cosmetic Ingredient Safety published its assessment of this ingredient in 2025. Its conclusion has two parts. The first is a conclusion of safety in cosmetics in the present practices of use, bounded at concentrations up to 0.005 per cent. The second is a statement that the available data are insufficient to make that determination at concentrations greater than 0.005 per cent [7].

The second part is the one that gets dropped, and it is the operative limit. It describes the evidence the panel received rather than the behaviour of the molecule: insufficient data is a statement about a submission, and it is neither a finding of harm above that concentration nor a clearance below it beyond what the panel wrote.

This site does not describe any compound as safe. The sentence above is a named panel's dated conclusion, reported as that, and this page neither adopts it nor argues with it.

What the two trials posted, reported in full

The National Institute of Neurological Disorders and Stroke ran two randomised trials of this peptide applied to the skin in blepharospasm, and both posted adverse event tables to the registry. Both are reported here in full, because a page that quotes a selected row from a table it cites has reported something other than the table.

The first trial posted no serious adverse event in either arm, and one non-serious term: minor self-limited eyelid irritation in 2 of 12 on the active cream and 2 of 12 on placebo. The registry adds that an ophthalmology consultation was obtained in all four cases and that no change to the study procedure was needed [17]. The published paper on the same trial reports no significant adverse events across its 24 participants [5].

The second trial posted six event terms across three arms of 3, 2 and 3, and every one of them affected a single participant. Two are recorded as serious: an automobile accident, 1 of 3 in the 0.05 per cent arm, and a case of blepharitis, 1 of 3 in the placebo arm. Four are not: puffiness of the lower eyelid, and high blood pressure due to not taking blood pressure medication, each 1 of 3 in the 0.05 per cent arm; and tingling in both eyelids after cream application, and weakness following botulinum toxin injection, each 1 of 3 in the placebo arm and both flagged in the registry as expected events [18].

The group totals follow from that and are given so the table is reproduced rather than described: serious events in 1 of 3, 0 of 2 and 1 of 3 across the 0.05 per cent, 0.025 per cent and placebo arms, and non-serious events in 2 of 3, 0 of 2 and 2 of 3 across the same three [18]. The 0.025 per cent arm posted no event of any kind.

One of those carries a note that travels with it. Against the automobile accident the registry records that the subject was the driver, that the subject was on study medication, and that the subject reported that worsening of blepharospasm may have contributed to the accident [18]. That is the registry's own wording. This page adds nothing to it in either direction, and in particular does not judge the event unrelated to what was applied to the eyelid.

Eight participants across arms of 3, 2 and 3 cannot settle anything in either direction, and the arm sizes are given here so a reader can see that for themselves. The trial is recorded as terminated with no reason stated in the registry, and it was never published [18]. [Human RCT] [5] [17] [18]

The one independent cell measurement

One laboratory measured what a solution of this peptide does to the proliferation of three cell types: human embryonic kidney cells, human neuroblastoma cells and primary skin fibroblasts, using a formazan-based assay, and calculated the concentration that halves proliferation for each [13].

The effect was dose dependent and appeared at concentrations 18 to 10,000 times higher than the reference compound doxorubicin required, depending on the cell line [13]. That is a large margin, and cells in a dish are not skin with a circulation and a barrier over it. The measurement is recorded here because it is the only independent cytotoxicity work found, not because it establishes a risk.

The authors' stated reason for running it is worth repeating and is a comment on the record rather than on the molecule: the toxicity data available to them came from the manufacturer [13]. [In-vitro] [13]

Injection, which is not a labelled route

One published case report describes a 45-year-old woman who received injections of this ingredient into the forehead and temples and developed redness, nodules and abscesses at the injection sites within a week. Culture of the pus grew Mycobacterium abscessus, and the lesions resolved over five months of clarithromycin and moxifloxacin [14].

One case is one case, and the report is about a procedure rather than about the molecule. This is a cosmetic ingredient formulated to be applied to the surface of skin, and an organism cultured from an injection site is a statement about what was introduced through the skin rather than about what the peptide does.

It is on this page because the practice exists and a reader searching this ingredient should meet it here rather than nowhere. [Anecdote] [14]

The measurement that bounds every question above

A US Food and Drug Administration laboratory applied an oil-in-water emulsion containing 10 per cent of this peptide to human cadaver skin at 2 mg per square centimetre, left it 24 hours, then washed the surface, tape-stripped the layers, heat-separated epidermis from dermis and read each fraction by mass spectrometry against stable isotope-labelled internal standards. Most of it washed off. Of the applied dose, 0.22 per cent was in the outer layer and 0.01 per cent in the epidermis. None was detected in the dermis or in the fluid collected beneath the skin [6].

That is an efficacy measurement in origin and it bounds the safety questions too, in both directions. A molecule that was not detected below the epidermis at 10 per cent, which is far above what a finished product carries, has a small systemic question attached to it. And the same measurement is the reason the cell work above sits where it does: a concentration that halves proliferation in a dish is reached by cells in a dish, and the arrival data says how much of an applied dose gets past the surface.

Excised skin in a diffusion cell is not living skin, and 24 hours is not repeated daily use. Both limits belong to the measurement and neither of them turns it into an argument. [In-vitro] [6]

What has not been characterised

Set out plainly, so the shape of the gap is visible rather than implied. Nothing published characterises repeated daily use of this ingredient over months or years in a person. The two trials that measured anything clinically ran in an eye condition, at 24 and 8 participants, and one of them was terminated with no reason stated [5] [18]. The panel's assessment describes present practices of use rather than following anyone.

Nothing published measures what the ingredient does at concentrations above the bound the panel named, which is the panel's own stated position rather than this site's inference [7]. And nothing published measures the oxidised form's behaviour: an analytical study found that form present in finished products alongside the intact molecule, and what it does was not characterised [15].

One exposure on this page is not the labelled one and cannot stand in for it. The injections in the case report bypass the barrier the arrival measurement is about entirely, so that report describes neither what a cream does nor what the molecule does. This page does not let it fill either space.

And nothing here describes acetyl octapeptide-3, the eight amino acid extension of this sequence sold as the stronger version. It is a different molecule with a record of its own, and what that record holds is set out on the acetyl octapeptide-3 safety record, linked under Safety records this page refers to at the foot of this page. The measurement above was made on this molecule and does not transfer to that one.

Our takeThe most common error made about this ingredient's safety record is quoting half of the 2025 panel conclusion. The panel reached a conclusion of safety in cosmetics bounded at 0.005 per cent and said in the same breath that the data are insufficient to reach that conclusion above it. Read alongside the arrival measurement, where 10 per cent applied to human skin put nothing below the epidermis, the picture is of a molecule whose exposure is small and whose upper bound is a gap in the submitted data rather than a finding about the chemistry.

Talk to a licensed clinician about anything concerning your health.

Frequently asked questions

References

1. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002. PMID 18498523 DOI 10.1046/j.1467-2494.2002.00153.x
2. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013. PMID 23417317 DOI 10.1007/s40257-013-0009-9
3. Wang Y, Wang M, Xiao XS, Pan P, Li P, Huo J. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. J Cosmet Laser Ther. 2013. PMID 23607739 DOI 10.3109/14764172.2012.759234
4. Wang Y, Wang M, Xiao XS, Huo J, Zhang WD. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013. PMID 23464592 DOI 10.3109/14764172.2013.769273
5. Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013. PMID 23146065 DOI 10.1111/ene.12009
6. Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015. PMID 24754410 DOI 10.3109/15569527.2014.894521
7. Johnson W Jr, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Marks JG Jr, Peterson LA, Shank RC, Slaga TJ, Snyder PW, Fiume M, Heldreth B. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025. PMID 40673537 DOI 10.1177/10915818251340391
8. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID 40565185 DOI 10.3390/ijms26125722
9. An JH, Lee HJ, Yoon MS, Kim DH. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019. PMID 33911590 DOI 10.5021/ad.2019.31.3.263
10. Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015. PMID 25497319 DOI 10.1016/j.ejps.2014.12.006
11. Lim SH, Sun Y, Thiruvallur Madanagopal T, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Sci Rep. 2018. PMID 29371611 DOI 10.1038/s41598-017-18454-z
12. Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022. PMID 35302659 DOI 10.1111/ics.12770
13. Grosicki M, Latacz G, Szopa A, Cukier A, Kieć-Kononowicz K. The study of cellular cytotoxicity of argireline - an anti-aging peptide. Acta Biochim Pol. 2014. PMID 24644551
14. Chen CF, Liu J, Wang SS, Yao YF, Yu B, Hu XP. Mycobacterium abscessus infection after facial injection of argireline: A case report. World J Clin Cases. 2021. PMID 33748252 DOI 10.12998/wjcc.v9.i8.1996
15. Kluczyk A, Ludwiczak J, Modzel M, Kuczer M, Cebrat M, Biernat M, Bąchor R. Argireline: Needle-Free Botox as Analytical Challenge. Chem Biodivers. 2021. PMID 33482052 DOI 10.1002/cbdv.202000992
16. Lum K, M Hirpara M, Pham C, Nguyen M, Mesinkovska N. Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature. J Drugs Dermatol. 2025. PMID 40196949
17. ClinicalTrials.gov. NCT00942851, a randomized triple-masked placebo-controlled trial of topical acetyl hexapeptide-8 at 0.005 per cent in 24 patients with blepharospasm, sponsored by the National Institute of Neurological Disorders and Stroke with BCN Peptides as collaborator. Completed October 2010. Results posted: primary outcome 3.71 months active against 3.03 months placebo; disability scale change at three months 30.89 per cent active against 32.32 per cent placebo. No statistical analysis is posted for any outcome. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2026. NCT00942851
18. ClinicalTrials.gov. NCT01750346, a randomized double-masked trial of topical acetyl hexapeptide-8 at 0.05 and 0.025 per cent against placebo in blepharospasm, sponsored by the National Institute of Neurological Disorders and Stroke, enrolling 8 participants across three arms. Recorded as TERMINATED with the reason field empty. Results posted: Jankovic scale at two months, where a higher score is worse, 6 and 7 in the active arms against 4.33 on placebo; one withdrawal for an adverse event in the highest-concentration arm. The registry's own background text states the trial was run because the concentration used in the earlier study was not very effective. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2026. NCT01750346
19. ClinicalTrials.gov. NCT01381484, a randomized triple-masked Phase 3 trial of a 10 per cent Argireline gel in 70 participants with periorbital wrinkles, sponsored by Mahidol University with Pacific Health Foundation as collaborator, completed September 2009. No results are posted and no publication was located. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2026. NCT01381484
20. ClinicalTrials.gov. NCT02597777, a randomized quadruple-masked pilot trial of topical acetyl hexapeptide-8 at 10 per cent in a lotion base against the same base, in 14 participants, primary outcome physician-graded shine at four weeks, sponsored by the University of California, Davis, completed February 2016. No results are posted and no publication was located. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2026. NCT02597777
21. ClinicalTrials.gov. Registry sweep for argireline, acetyl hexapeptide-8, acetyl hexapeptide-3, acetyl octapeptide-3, acetyl octapeptide-8 and SNAP-8 peptide, run through the v2 API on 23 August 2026. Six records returned for the hexapeptide, of which four name it as the isolated intervention and two carry it inside a multi-ingredient product (NCT03878381, a compounded cream listing twelve actives in 10 participants; NCT06143033, a single-arm eye serum with twenty-four declared ingredients in 35 participants). The three octapeptide queries each returned no record. ClinicalTrials.gov. 2026. ClinicalTrials.gov
22. United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
23. Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 23 August 2026. United States Code. 2026. Source document
24. Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 23 August 2026. Electronic Code of Federal Regulations. 2026. Source document